Table 1 Clinical and demographic characteristics of study participants at study begin
From: Performance of synacthen test in chronic hemodialysis patients
Total (N = 28) | |
|---|---|
Median age in years at study begin (IQR) | 70.50 (63.00, 75.50) |
Gender (male) | 20 (71.4%) |
Caucasian | 25 (89.3%) |
Previous kidney transplantation | 2 (7.1%) |
Previous glucocorticoid treatment ≥ 2weeks (≥ 1year ago) | 5 (17.9%) |
Median HD vintage in months (IQR) | 36.50 (15.50, 77.50) |
Dialysis access: Arteriovenous fistula / graft | 24 (85.7%) |
Cause of end stage kidney disease (ESKD) | |
- Vascular - Diabetes - ADPKD - Glomerulonephritis - Tubulointerstitial disease - Other*/ Unknown | 11 (39.3%) 10 (35.7%) 1 (3.6%) 4 (14.3%) 1 (3.6%) 11 (39.3) |
Patients with multiple causes of ESKD | 7 (25%) |
Native kidney biopsy | 10 (35.7%) |
Comorbidities | |
- Coronary artery disease - Congestive heart failure - Hypertension - Peripheral artery occlusive disease - Diabetes mellitus - Obesity - Neoplastic disease - Other** | 9 (32.1%) 7 (25.0%) 24 (85.7%) 14 (50.0%) 13 (46.4%) 6 (21.4%) 4 (14.3%) 7 (25.0%) |
Patients with multiple comorbidities | 25 (89.3%) |
Concomitant medication | |
- Loop diuretics - Thiazide diuretics - RAAS inhibitor - CCB blocker - BB - Insulin | 17 (60.7%) 7 (25.0%) 10 (35.7%) 6 (21.4%) 18 (64.3%) 7 (25.0%) |